Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BET inhibition
Biotech
Nuvation halts BET inhibitor after considering phase 1 data
After taking a look at phase 1 data, Nuvation will halt work on its one-time lead BD2-selective BET inhibitor while considering the program’s future.
James Waldron
Aug 5, 2024 11:02am
Novartis only wanted pelabresib, but MorphoSys had other ideas
Apr 12, 2024 8:53am
MorphoSys fails secondary in blood cancer trial, sinking stock
Nov 21, 2023 5:52am
Vyne swings behind BET, seeks partner for failed eczema drug
Mar 10, 2023 9:30am
Turning Gilead's Zydelig against triple-negative breast cancer
Mar 12, 2020 8:00am
Aptose signs $125M-plus BET inhibitor deal with Ohm
Mar 7, 2018 9:32am
